Dear Sir,

Acquired inhibitors against factor VIII in patients without hemophilia are the most common type of acquired specific antibodies but still a rare occurrence. We describe a 63-year-old man who presented with an idiopathic acquired hemophilia, revealed by a spontaneous hematoma in the thigh. No particular etiology was evidenced. Factor V was less than 1% with an inhibitor of 6 Bethesda Units. He was first treated with prednisone (1 mg/kg) in combination with high-dose intravenous γ-globulins (IVIg): 400 mg/kg for 5 days. The inhibitor disappeared, then reappeared when corticosteroids were tapered with bleeding diathesis and a weak inhibitor against porcine factor. Several hemorrhagic events were treated by prothrombin complex concentrate (CPP) and activated PPC. After five cycles of cyclophosphamide, the inhibitor seems to be eradicated and factor VIIIC increased to 41%. At that time, nodular opacity of the lower lobe was observed in the right lung. Neoplasia was suspected on biopsy, and lobectomy was performed after IVIg and activated PPC infusion. Microscopic examination revealed typical tubercular lesions and the patient was then treated with antituberculous agents. Thirty-three months after surgery, factor VIIIC inhibitor has not reappeared and factor VIIIC is completely normalized at 160%.

Acquired inhibitors to factor VIII in non-hemophilic patients are rare and mostly encountered in patients over 50 years of age. As reported by Green and Lechner [1] in 1981, they may develop in association with autoimmune disorders, pregnancy, malignancy or drugs, but in 46% of patients there is no detectable underlying disorder. Our patient suffered from pulmonary tuberculosis: this etiology was not reported among the various disorders listed in this survey of 215 non-hemophilic patients. However, acquired factor VIIIC inhibitor has been described associated with pulmonary disease: lung abscess [2], bronchogenic and lung carcinoma [3, 4]. Furthermore, tuberculosis was occasionally described in association with an inhibitor against human factor V [5] protein which shares different homologous sequences with factor VIIIC. Cyclophosphamide, most of the time combined with prednisone, has been shown to be effective for long-term immunosuppression [6], and the inhibitor seems to disappear in our patient before antitu-
berculous treatment. It is possible that cyclophosphamide, combined with infusion of a new
batch of IVIg before surgery, has played a role in this disappearance.
This observation is, to our knowledge, the first report on acquired hemophilia associated with
tuberculosis. Immunosuppression and IVIg infusion, but also surgery and antituberculous agents
might explain the complete recovery of our patient, as well as spontaneous disappearance of the
autoantibody.
Management of such patients still remains controversial, and only few prospective trials are in
progress because of the scarcity of this disorder.
References
Green D, Lechner K: A survey of 215 non-hemophilic patients with inhibitors to factor VIII.
Ganly PS, Isaacs JD, Laffan MA, Haslett C, Hows JM: Acquired factor VIII inhibitor associated
Al-Ismail SAD, Parry DH, Moisey CU, Bloom AL: Factor VIII inhibitor and bronchogenic

De Cataldo F, Baudo F, Redaelli R, Pezzetti L: Acquired factor VIII·C inhibitor (IgG) and
positive direct Coomb’s test (IgM) in a patient with lung carcinoma. Scand J Haematol
1984;33:171-176.
Nesheim ME, Nichols WL, Cole TL, Houston JG, Schenk RB, Mann KG, Bowie EJW: Isolation
Green D, Rademaker AW, Briët E: A prospective randomized trial of prednisone and
cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost
1993;70:753-757.

320
Haemostasis 1996;26:319-320
Aurousseau/Eclache/Fain/Thomas